ID   A-673 clone Asp114
SY   A673 clone Asp114; ASP114; Asp114; A673/TR/shEF
DR   cancercelllines; CVCL_JM58
DR   GEO; GSE27524
DR   PRIDE; PXD002765
DR   Wikidata; Q54606058
RX   PubMed=17438102;
RX   PubMed=23940108;
RX   PubMed=28062706;
CC   Problematic cell line: Misclassified. Parent cell line (A-673) was originally thought to be a rhabdomyosarcoma cell line but is an Ewing sarcoma cell line.
CC   Population: Caucasian.
CC   Characteristics: Transfected with a construct harboring a doxycycline-inducible shRNA against the EWSR1-FLI1 fusion protein.
CC   Knockout cell: Method=shRNA knockdown; HGNC; 3508; EWSR1 (Note=EWSR1-FLI1 fusion).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 3749; FLI1 (Note=EWSR1-FLI1 fusion).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala119Glnfs*5 (c.353_354dupCA) (c.354_355insCA); Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0080 ! A-673
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 30-01-24; Version: 16
RX   PubMed=17438102; DOI=10.1158/1078-0432.CCR-06-1762;
RA   Carrillo J., Garcia-Aragoncillo E., Azorin D., Agra N., Sastre A.,
RA   Gonzalez-Mediero I., Garcia-Miguel P., Pestana A., Gallego S.,
RA   Segura D., Alonso J.;
RT   "Cholecystokinin down-regulation by RNA interference impairs Ewing
RT   tumor growth.";
RL   Clin. Cancer Res. 13:2429-2440(2007).
RX   PubMed=23940108; DOI=10.1101/gr.151340.112;
RA   Bilke S., Schwentner R., Yang F., Kauer M., Jug G., Walker R.L.,
RA   Davis S., Zhu Y.-L.J., Pineda M.A., Meltzer P.S., Kovar H.;
RT   "Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma
RT   and prostate cancer.";
RL   Genome Res. 23:1797-1809(2013).
RX   PubMed=28062706; DOI=10.1158/1535-7163.MCT-16-0235;
RA   Radic-Sarikas B., Tsafou K.P., Emdal K.B., Papamarkou T., Huber K.V.M.,
RA   Mutz C., Toretsky J.A., Bennett K.L., Olsen J.V., Brunak S., Kovar H.,
RA   Superti-Furga G.;
RT   "Combinatorial drug screening identifies Ewing sarcoma-specific
RT   sensitivities.";
RL   Mol. Cancer Ther. 16:88-101(2017).